A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer

A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer

Abstract Background Dalpiciclib (SHR6390) is a novel inhibitor of cyclin-dependent kinase 4/6 which demonstrated promising anti-tumor potency in preclinical models. This first-in-human study was conducted to evaluate the tolerability, pharmacokinetics, safety, and preliminary antitumor activity of d...

Full description

Bibliographic Details
Main Authors: Pin Zhang, Binghe Xu, Lin Gui, Wenna Wang, Meng Xiu, Xiao Zhang, Guilan Sun, Xiaoyu Zhu, Jianjun Zou
Format: Article
Language:English
Published: BMC 2021-04-01
Series:Biomarker Research
Subjects:
Cyclin-dependent kinase 4/6 inhibitor
Advanced breast cancer
First-in-human trial
Online Access:https://doi.org/10.1186/s40364-021-00271-2

Internet

https://doi.org/10.1186/s40364-021-00271-2

Similar Items